.jpg?w=340&itok=xrpB93pQ "IPT discussed in technical publications."){kind=icon}
Biologic viral safety is entering a new phase. Updated global ICH guidance is reshaping how manufacturers approach risk based controls, modern analytics and manufacturing innovation. In this PharmTech feature, John M. e...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Ensuring better patient outcomes through decentralised & hybrid trials
ICON CEO Steve Cutler discusses how the research industry has changed in the past year, concluding that decentralised models are helping to improve patient outcomes and bring treatments to market faster (page 12).
-
.jpg?w=545&itok=Rwqj2ePn "IPT discussed in technical publications.")
Anatomic pathology in the digital era
Greg Cox, Director ICON Laboratory Services, shares his perspective on how integrating digital pathology into clinical trials can benefit study outcomes and data integrity.
-
Trailblazing women stress importance of diversity in pharma
Nuala Murphy, President of Clinical Research Services at ICON, discusses how increasing diversity is a key area of focus for ICON, both in terms of patient diversity and diversity in the organisation.
-
The central role of Interactive Response Technology in today's clinical trials
Michelle Lynskey, Global Head of Interactive Response Technology and Clinical Supplies Management, offers her insights on the role of IRT in clinical trials (pages 42-43).
-
A trusted partner for clinical development
ICON CEO Steve Cutler chats with Newsweek, on ICON’s role in the development of much needed medicines. The interview (page 12 of PDF) is part of a special report on Ireland.
-
The pursuit of patient diversity in clinical trials
Nuala Murphy, President of Clinical Research Services, provides expert commentary on the importance of patient diversity in clinical trials.
-
The tangled web of large outsourced providers
ICON’s $12 billion acquisition of PRA Health Sciences is discussed as part of the changing CRO landscape.
-
ICON acquisition confirms its status as a global powerhouse in clinical research
An interview in which CEO Dr. Steve Cutler provides an overview of ICON’s evolution and drivers over the past few years from the pandemic to the recent PRA Health acquisition.
-
The new cancer treatment frontier: Why clinical trials need to keep pace with innovations in cancer research
Andreas Dreps and Martin Lachs discuss the recent advances in cancer research and why oncology clinical trials must make use of these developments to stay ahead of the curve
-
Alzheimer’s: the search for a cure
An interview in which Peter Schueler discusses the current landscape of Alzheimer’s research and recently published study results.
